نتائج البحث - Laila Arash

  • يعرض 1 - 8 نتائج من 8
تنقيح النتائج
  1. 1
    Pharmacokinetics, pharmacodynamics, and safety of moss‐aGalactosidase A in patients with Fabry disease

    Pharmacokinetics, pharmacodynamics, and safety of moss‐aGalactosidase A in patients with Fabry disease حسب Julia B. Hennermann, Laila Arash‐Kaps, György Fekete, Andreas Schaaf, Andreas Büsch, Thomas Frischmuth

    منشور في 2019
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Ocular Signs Correlate Well with Disease Severity and Genotype in Fabry Disease

    Ocular Signs Correlate Well with Disease Severity and Genotype in Fabry Disease حسب Susanne Pitz, Gisela Kalkum, Laila Arash, Nesrin Karabul, Andrea Sodi, Sylvain Larroque, Michael Beck, Andreas Gal

    منشور في 2015
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Alpha-mannosidosis: correlation between phenotype, genotype and mutant MAN2B1 subcellular localisation

    Alpha-mannosidosis: correlation between phenotype, genotype and mutant MAN2B1 subcellular localisation حسب Line Borgwardt, Hilde Monica Frostad Riise Stensland, Klaus J Olsen, Flemming Wibrand, Helle Bagterp Klenow, Michael Beck, Yasmina Amraoui, Laila Arash, J. Fogh, Øivind Nilssen, Christine í Dali, Allan M. Lund

    منشور في 2015
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Impact of immunosuppressive therapy on therapy‐neutralizing antibodies in transplanted patients with Fabry disease

    Impact of immunosuppressive therapy on therapy‐neutralizing antibodies in transplanted patients with Fabry disease حسب Malte Lenders, Daniel Oder, Albina Nowak, Sima Canaan‐Kühl, Laila Arash‐Kaps, Christiane Drechsler, Boris Schmitz, Peter Nordbeck, Julia B. Hennermann, Christoph Kampmann, Stefan Reuter, Stefan‐Martin Brand, Christoph Wanner, E. Brand

    منشور في 2017
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    A randomized, placebo-controlled clinical trial evaluating olipudase alfa enzyme replacement therapy for chronic acid sphingomyelinase deficiency (ASMD) in adults: One-year results

    A randomized, placebo-controlled clinical trial evaluating olipudase alfa enzyme replacement therapy for chronic acid sphingomyelinase deficiency (ASMD) in adults: One-year results حسب Melissa Wasserstein, Robin Lachmann, Carla E. M. Hollak, Laila Arash‐Kaps, Antonio Barbato, Renata C. Gallagher, Roberto Giugliani, Norberto Guelbert, Takayuki Ikezoe, Olivier Lidove, Paulina Mabe, Eugen Mengel, Maurizio Scarpa, Eubekir Senates, Michel Tchan, Jesús Villarrubia, Yixin Chen, Sandy A. Furey, Beth L. Thurberg, Atef Zaher, Monica Kumar

    منشور في 2022
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    Enzyme replacement therapy for mucopolysaccharidosis VI: Growth and pubertal development in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase

    Enzyme replacement therapy for mucopolysaccharidosis VI: Growth and pubertal development in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase حسب Celeste Decker, Zi‐Fan Yu, Roberto Giugliani, Ida Vanessa Döederlein Schwartz, Nathalie Guffon, Elisa Leão Teles, Clara Sá-Miranda, J. E. Wraith, Michael Beck, Laila Arash, Maurizio Scarpa, David Ketteridge, John J. Hopwood, Barbara Plecko, Robert D. Steiner, Chester B. Whitley, Paige Kaplan, Stuart J. Swiedler, Susan E. Conrad, Paul Harmatz

    منشور في 2010
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    Enzyme replacement therapy for mucopolysaccharidosis VI: evaluation of long‐term pulmonary function in patients treated with recombinant human <i>N</i>‐acetylgalactosamine 4‐sulfatase

    Enzyme replacement therapy for mucopolysaccharidosis VI: evaluation of long‐term pulmonary function in patients treated with recombinant human <i>N</i>‐acetylgalactosamine 4‐sulfat... حسب Paul Harmatz, Zi‐Fan Yu, Roberto Giugliani, Ida Vanessa Döederlein Schwartz, Nathalie Guffon, Elisa Leão Teles, Clara Sá-Miranda, J. E. Wraith, Michael Beck, Laila Arash, Maurizio Scarpa, David Ketteridge, John J. Hopwood, Barbara Plecko, Robert D. Steiner, Chester B. Whitley, Paige Kaplan, Stuart J. Swiedler, Karen Hardy, Kenneth I. Berger, Celeste Decker

    منشور في 2010
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  8. 8
    Clinical course of sly syndrome (mucopolysaccharidosis type VII)

    Clinical course of sly syndrome (mucopolysaccharidosis type VII) حسب Adriana M. Montaño, Lock Hock Ngu, Robert D. Steiner, Brett H. Graham, Marina Szlago, Robert M. Greenstein, Mercédes Pineda, Antonio González‐Meneses, Mahmut Çöker, Dennis Bartholomew, Mark S. Sands, Raymond Wang, Roberto Giugliani, Alfons Macaya, Gregory M. Pastores, Anastasia Ketko, Fatih Süheyl Ezgü, Akemi Tanaka, Laila Arash, Michael Beck, Rena E. Falk, Kaustuv Bhattacharya, José Francisco da Silva Franco, Klane K. White, Grant A. Mitchell, Loreta Cimbalistienė, Max Holtz, William S. Sly

    منشور في 2016
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: